California Department of Alcohol and Drug Programs

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Retrieved on: 
Thursday, October 20, 2022
CDE, Merck, Therapy, Mayo Clinic, Institute, Treatment, American Association, Association, Congress, The Pauly D Project, Priority review, BTD, California Department of Alcohol and Drug Programs, Cancer, NMPA, Infection, CHB, Motherboard, Degenerative disease, Hepatology, Odds, FDA, Biotechnology, RPD, AstraZeneca, FTD, DC, National Medical Products Administration, Hepatitis, Multimedia, TKI, Jingxi Nanfang Hospital station, Apoptosis, AASLD, IAP, Unity Biotechnology, Southern Medical University, Patient, Stock exchange, Center for Drug Evaluation and Research, ODD, CML, MD Anderson Cancer Center, Institute of Liver and Biliary Sciences, Center, Dana–Farber Cancer Institute, Pharmaceutical industry, Vaccine, Fine chemical, Pfizer, EU

The AASLD Annual Meeting is one of the most anticipated scientific gatherings in the field of hepatology.

Key Points: 
  • The AASLD Annual Meeting is one of the most anticipated scientific gatherings in the field of hepatology.
  • This year's congress will take place both online and in-person in Washington, DC, the United States, during November 4th to 8th, 2022.
  • Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
  • Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Retrieved on: 
Monday, June 13, 2022
FTD, TLS, Congress, Follicular lymphoma, Mantle cell lymphoma, The Pauly D Project, NHL, Biotechnology, RPD, California Department of Alcohol and Drug Programs, Therapy, Multimedia, CRS, Tumor lysis syndrome, AstraZeneca, Dana–Farber Cancer Institute, Motherboard, PD, Center for Drug Evaluation and Research, CHB, National Medical Products Administration, IAP, CDE, DLT, ORR, Pharmacokinetics, Center, ODD, Infection, MCL, Degenerative disease, BTK, BTD, Merck, CLL, Patient, Lymphatic system, CR, PRS, MD Anderson Cancer Center, CML, T cell, Odds, EHA, Hepatitis, TKI, Treatment, Cancer, Unity Biotechnology, Priority review, NMPA, FDA, Stock exchange, PR, Mayo Clinic, Apoptosis, Safety, Pharmaceutical industry, Vaccine, Fine chemical, MD, EU, Pfizer

Lisaftoclax is the first Bcl-2 inhibitor developed and entering clinical development in China, and is also the second such agent entering pivotal trials globally.

Key Points: 
  • Lisaftoclax is the first Bcl-2 inhibitor developed and entering clinical development in China, and is also the second such agent entering pivotal trials globally.
  • Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, commented, "Lisaftoclax is a key drug candidate in Ascentage Pharma's apoptosis-targeted pipeline.
  • We will press ahead with the clinical development of lisaftoclax in efforts to bring a much-needed new treatment option to patients."
  • As of January 1, 2022, 40 patients had been treated with lisaftoclax (dose range 20-800 mg), including 20 who remain in the trial.

ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%

Retrieved on: 
Tuesday, June 7, 2022
FTD, MD Anderson Cancer Center, CDE, The Pauly D Project, Society, Biotechnology, Safety, RPD, ASH, California Department of Alcohol and Drug Programs, CML, Breast cancer, Treatment, Cancer, Unity Biotechnology, Large-cell lung carcinoma, Center, ODD, The Best of Ash, Therapy, Multimedia, Priority review, Infection, BCR-ABL, NMPA, FDA, Stock exchange, Patient, Odds, AstraZeneca, Degenerative disease, Dana–Farber Cancer Institute, Motherboard, GIST, Hepatitis, BTD, Gastrointestinal stromal tumor, Merck, Center for Drug Evaluation and Research, TKI, NSCLC, Mayo Clinic, IAP, Apoptosis, FAK, National Medical Products Administration, Mutation, Mesothelioma, Pharmaceutical industry, Fine chemical, Pfizer, EU

Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.

Key Points: 
  • Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
  • Olverembatinib can effectively target a spectrum of BCR-ABL mutants, including the T315I mutation.
  • Meanwhile, olverembatinib is being investigated for the treatment of gastrointestinal stromal tumor (GIST) in China.
  • In July 2021, Ascentage Pharma and Innovent Biologics (1801.HK) reached the agreement regarding the joint development and commercialization of olverembatinib in the oncology field in China.

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL

Retrieved on: 
Tuesday, March 15, 2022
MSD, BTD, ODD, National Medical Products Administration, Western world, D-project, NMPA, CHB, BTK, Lymphoid neoplasms with plasmablastic differentiation, New Drug Application, TKI, NDA, IAP, Treatment, CML, Center for Drug Evaluation and Research, Apoptosis, Multimedia, AstraZeneca, Population, Death, CLL, Priority review, Biotechnology, FTD, Patient, CDE, Therapy, Motherboard, California Department of Alcohol and Drug Programs, ORR, Mayo Clinic, Degenerative disease, Leukemia, Cancer, HIV disease progression rates, Dana–Farber Cancer Institute, Lymphatic system, Phase II, MD Anderson Cancer Center, Center, Safety, Ageing, Hepatitis, SEER, Incidence, Infection, Stock exchange, Unity Biotechnology, Pharmaceutical industry, Fine chemical, EU, Pfizer

APG2575CC201 is a single-arm, open-label Phase II pivotal study designed to assess the efficacy and safety of lisaftoclax in patients with R/R CLL/SLL, with the overall response rate (ORR) as the primary endpoint.

Key Points: 
  • APG2575CC201 is a single-arm, open-label Phase II pivotal study designed to assess the efficacy and safety of lisaftoclax in patients with R/R CLL/SLL, with the overall response rate (ORR) as the primary endpoint.
  • CLL/SLL is a hematologic malignancy caused by mature B-cell neoplasms and is among the most common lymphoid neoplasms in the Western world.
  • Lisaftoclax is the first China-developed Bcl-2 inhibitor entering clinical development in China, and the second entering pivotal studies globally.
  • The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China.

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022
MSD, Priority review, Apoptosis, Drug resistance, BTD, AACR, American Association for Cancer Research, Center for Drug Evaluation and Research, Infection, CDE, CHB, FTD, H3K27me3, Research, Therapy, FAK, Unity Biotechnology, Degenerative disease, Stock exchange, AstraZeneca, Mutation, MD Anderson Cancer Center, National Medical Products Administration, KRAS, Multimedia, NMPA, IAP, Cancer, Mesothelioma, Motherboard, EED, Dana–Farber Cancer Institute, Patient, Treatment, TKI, California Department of Alcohol and Drug Programs, American Association, TP53, 2021 Essex County Council election, Center, Autophagy, Hepatitis, GDP, Mayo Clinic, Biotechnology, CML, Association, ODD, The Pauly D Project, Pharmaceutical industry, Fine chemical, Communications satellite, Potash, EU, Pfizer

The AACR annual meeting is one of the world's largest and long-standing scientific gatherings in the field of cancer research.

Key Points: 
  • The AACR annual meeting is one of the world's largest and long-standing scientific gatherings in the field of cancer research.
  • This year's AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
  • These six abstracts from Ascentage Pharma include:
    Time: 9:00 AM 12:30 PM CST, April 13, 2022
    BCL-2 mutation is a key mechanism driving the drug-resistance to BCL-2 inhibitors.
  • Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.

Clover and Ascentage Pharma Announce Clinical Collaboration to Evaluate Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, in Combination with IAP Antagonist, APG-1387 for the Treatment of Peritoneal Carcinomatosis

Retrieved on: 
Thursday, December 9, 2021
MSD, CHB, Vaccine, CEO, DR4, Center, Infection, TRAIL, Severe acute respiratory syndrome coronavirus 2, SCB-2019, Forward-looking statement, GLOBE, IAPS, MD Anderson Cancer Center, Dana–Farber Cancer Institute, Cancer, Patient, Unity Biotechnology, Bladder cancer, National Medical Products Administration, TKI, FTD, SMAC, Degenerative disease, Apoptosis, Priority review, AstraZeneca, Chief executive officer, Biotechnology, The Pauly D Project, Center for Drug Evaluation and Research, NMPA, Therapy, DR5, HBV, California Department of Alcohol and Drug Programs, Safety, Mayo Clinic, Hepatitis, IAP, CpG, ODD, Partnership, Stock exchange, COVID-19, BTD, Treatment, CDE, Malignant pleural effusion, CML, Motherboard, Pharmaceutical industry, Fine chemical

Clover also plans to initiate new Phase 1 trials for SCB-313 in new indications, such as bladder cancer, in 2022.

Key Points: 
  • Clover also plans to initiate new Phase 1 trials for SCB-313 in new indications, such as bladder cancer, in 2022.
  • Discovered and developed by Ascentage Pharma, APG-1387 is a potent and highly specific next-generation IAP antagonist and the first IAP antagonist entering clinical development in China.
  • We hope APG-1387 in combination with Clovers SCB-313 will demonstrate synergistic effect," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma.
  • We look forward to working closely with Clover to advance this clinical collaboration which hopefully will offer a new treatment option to patients with peritoneal carcinomatosis.

ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting

Retrieved on: 
Friday, November 5, 2021
MSD, NDA, Population, Progression-free survival, Biotechnology, Degenerative disease, IAP, Treatment, Dana–Farber Cancer Institute, Cancer, Efficacy, QOD, Therapy, Mayo Clinic, Diagnosis, TKI, BCR, Stock exchange, PFS, Mahr, PK, Leukopenia, Motherboard, Hepatitis, California Department of Alcohol and Drug Programs, Thrombocytopenia, Male, Patient, Center for Drug Evaluation and Research, D-project, Center, FTD, MMR, Mutation, Multimedia, Trae tha Truth, Anemia, CML, Apoptosis, AstraZeneca, OS, ODD, Priority review, Infection, MD Anderson Cancer Center, BCR-ABL, CDE, 2021 Essex County Council election, Unity Biotechnology, BTD, CHR, Pharmaceutical industry, Medical imaging, Health insurance, Fine chemical

Olverembatinib was orally administered once every other day (QOD)in 28-day cycles and at 11 dose cohorts ranging from 1 to 60 mg.

Key Points: 
  • Olverembatinib was orally administered once every other day (QOD)in 28-day cycles and at 11 dose cohorts ranging from 1 to 60 mg.
  • - From October 26, 2016, through February 2, 2021 (data cut-off date), 101 patients with CML-CP (n=86) or CML-AP (n=15) were enrolled and treated with olverembatinib.
  • In all, 84 (83.2%) patients received 2 prior lines of TKI-therapies, and 63 (62.4%) harbored the T315I mutation.
  • Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.